Browse categories and answer follow-up questions to refine your symptom profile.
Approach to the Critical Patient
Immediate stabilization
Unstable presentations
Hypotension
Escalate to resuscitation bay for shock physiology
If pulsus paradoxus with shock, pericardial tamponade pathway
Severe respiratory distress
Oxygen titrated to clinical targets
If impending respiratory failure, airway plan with tamponade precautions
Altered mental status
If persistent, shock pathway and alternate diagnosis pathway
Monitoring and access
Cardiac monitor
Continuous rhythm observation for atrial arrhythmia
12 lead ECG
If STEMI criteria, ACS pathway with pericarditis mimic check
IV access
Two large bore peripheral lines for unstable physiology
Point of care ultrasound
If hypotension, pericardial effusion and tamponade signs
Time critical exclusions
Acute coronary syndrome
If persistent pain or ischemic ECG features, ACS evaluation pathway
Pulmonary embolism
If hypoxia or pleuritic pain with risk factors, PE pathway
Aortic dissection
If tearing pain or pulse deficit, aortic syndrome pathway
Esophageal rupture
If severe vomiting with chest pain, mediastinitis pathway
Key concepts
Syndrome framing
Acute pericarditis
Inflammatory chest pain syndrome with pericardial irritation
Myopericarditis
Pericarditis with myocardial injury markers
Pericardial effusion
Fluid without mandatory inflammation
Cardiac tamponade
Hemodynamic compromise from elevated intrapericardial pressure
Diagnostic criteria
Acute pericarditis requires at least 2 of 4 criteria
Typical pericardial chest pain
Pericardial friction rub
New widespread ST elevation or PR depression
New or worsening pericardial effusion
PITFALLS
Common misses
STEMI misdiagnosis
Regional ST elevation with reciprocal changes favors STEMI over pericarditis
Tamponade without classic triad
Normotension possible in subacute effusions
Myocarditis overlap
Troponin elevation with LV dysfunction changes disposition and activity guidance
Anticoagulation or trauma history
Hemopericardium risk with small effusions still clinically important
History
Symptom pattern
Chest pain features
Pleuritic quality
Worse with inspiration or cough
Positional component
Worse supine
Better leaning forward
Radiation
Trapezius ridge or shoulder pain
Time course
Acute onset hours to days
Associated symptoms
Dyspnea
Worsening when supine suggests effusion
Fever
High fever suggests specific cause and higher risk
Viral prodrome
URI or GI illness preceding symptoms
Palpitations
Atrial arrhythmia consideration
Risk factors and secondary causes
Infectious exposures
Tuberculosis risk
Birth or travel in high prevalence regions
Bacterial risk
Immunosuppression
Recent thoracic surgery
Systemic disease
Autoimmune disorder history
SLE
Rheumatoid arthritis
Malignancy history
Lung cancer
Breast cancer
Lymphoma
Metabolic and renal
Advanced kidney disease
Uremic pericarditis consideration
Cardiac and iatrogenic
Recent MI
Early post infarction pericarditis
Dressler syndrome timing weeks
Recent cardiac procedure
Post pericardiotomy syndrome
Medication and bleeding risk
Oral anticoagulant use
Hemopericardium risk
Recent trauma
Blunt or penetrating chest trauma
Physical Exam
Core findings
Vital signs pattern
Fever
Persistent fever supports inflammatory or infectious cause
Tachycardia
Pain response or early hemodynamic compromise
Cardiac exam
Pericardial friction rub
Classically triphasic and transient
Heart sounds
Muffled sounds suggest effusion
Respiratory exam
Pleural rub or effusion signs
Pleuropericardial involvement consideration
Signs of effusion and tamponade
Clinical tamponade indicators
Hypotension
Shock physiology trigger
Jugular venous distension
Elevated JVP with dyspnea
Muffled heart sounds
Low sensitivity in practice
Dynamic indicators
Pulsus paradoxus
Drop in systolic BP with inspiration
Peripheral perfusion
Cool extremities
Delayed capillary refill
PITFALLS
Low sensitivity signs
Absence of rub
Does not exclude pericarditis
Clear lung fields
Compatible with both pericarditis and tamponade
Normal blood pressure
Possible in compensated tamponade
Differential Diagnosis
Life threatening mimics
Acute coronary syndrome
NSTEMI STEMI
ICD-10 I21
Pulmonary embolism
ICD-10 I26
Pleuritic pain with dyspnea or hypoxia
Aortic dissection
ICD-10 I71.0
Sudden severe pain with neuro deficit or pulse deficit
Tension pneumothorax
ICD-10 J93
Unilateral breath sound reduction with instability
Esophageal rupture
ICD-10 K22.3
Severe vomiting with chest pain and systemic toxicity
Cardiac tamponade
ICD-10 I31.4
Effusion with hemodynamic compromise
Pericardial and myocardial syndromes
Acute pericarditis
ICD-10 I30
Idiopathic or viral common in high income settings
Myopericarditis
Troponin elevation without predominant LV dysfunction
ICD-10 I40 I30 overlap coding per local convention
Perimyocarditis
Predominant myocarditis with pericardial involvement
LV dysfunction risk and arrhythmia risk
Pericardial effusion without inflammation
ICD-10 I31.3
Malignancy hypothyroidism uremia
Constrictive pericarditis
ICD-10 I31.0
Chronic right heart failure physiology
Neoplastic pericardial disease
ICD-10 C79.89 with I31.3
Recurrent or large effusion
Laboratory Tests
Inflammatory and cardiac markers
Inflammation and prognosis
C reactive protein
Elevation supports inflammatory phenotype
Trend supports treatment response guidance
Erythrocyte sedimentation rate
Supportive when CRP unavailable or discordant
Myocardial injury
High sensitivity troponin
Elevation suggests myopericarditis or alternate diagnosis
Dynamic rise fall pattern increases myocarditis or ACS concern
BNP or NT proBNP
Elevation supports myocardial stress or heart failure physiology
Etiology directed testing
Infection risk stratification
Blood cultures for febrile or toxic appearance
Two sets before antibiotics when bacterial concern
HIV testing when risk factors or unexplained course
Opportunistic infection consideration
TB testing when epidemiologic risk
IGRA or tuberculin based on local practice
Autoimmune screening when indicated
ANA with systemic symptoms
Rash arthritis serositis
Rheumatoid factor or anti CCP when inflammatory arthritis
Recurrent pericarditis association
Medication safety and baseline assessment
NSAID safety
Creatinine and electrolytes
CKD increases adverse renal risk
CBC
Baseline anemia or thrombocytopenia affects NSAID bleeding risk
Colchicine safety
Liver enzymes
Hepatic dysfunction increases toxicity risk
Creatinine and eGFR
Dose reduction for renal impairment
Pregnancy testing
Serum or urine hCG when relevant
Medication selection implications
Diagnostic Tests
Scoring Systems
Risk stratification for complications and admission
High risk features for inpatient management
Fever and systemic inflammation
Subacute onset
Large pericardial effusion
Cardiac tamponade
Failure of NSAID therapy
Immunosuppression
Oral anticoagulation
Trauma
Pericardial effusion size classification by echo
Small effusion
Echo free space less than 10 mm in diastole
Moderate effusion
Echo free space 10 to 20 mm in diastole
Large effusion
Echo free space more than 20 mm in diastole
ECG pattern recognition
Typical staged ECG evolution
Diffuse concave ST elevation
PR depression
ST normalization then T wave inversion
MRI
Indications
Suspected myocarditis overlap
LV dysfunction
Significant troponin elevation
Persistent symptoms with unclear diagnosis
Evaluation of active pericardial inflammation
Diagnostic utility
Pericardial edema and late gadolinium enhancement
Active inflammation markers guiding therapy duration
Myocardial edema and late gadolinium enhancement
Myocarditis phenotype and prognosis
Constraints
Hemodynamic instability
Defer to echocardiography and urgent interventions
Gadolinium in advanced renal failure
Nephrogenic systemic fibrosis risk considerations
CT
Indications
Alternate diagnosis evaluation
Pulmonary embolism aortic syndrome when suspected
Pericardial thickening calcification
Constrictive pericarditis workup support
Poor echo windows
Adjunct assessment of effusion and extracardiac findings
Findings
Pericardial enhancement
Inflammatory pericarditis support
Pericardial fluid density
High attenuation suggests hemopericardium
Risks
Contrast nephropathy
Higher risk in CKD and dehydration
Radiation exposure
Pediatric and pregnancy considerations
Ultrasound (or US)
Transthoracic echocardiography
Pericardial effusion assessment
Size distribution and chamber compression
Tamponade physiology assessment
Right atrial systolic collapse
Right ventricular diastolic collapse
Plethoric IVC with reduced inspiratory collapse
LV function assessment
Reduced EF suggests myocarditis overlap
Point of care ultrasound integration
Shock evaluation
Effusion with tamponade signs supports immediate drainage pathway
Serial reassessment
Worsening effusion size or new chamber collapse triggers escalation
Disposition
Admission and transfer
Inpatient criteria
High risk features present
Fever or systemic toxicity
Large effusion or tamponade physiology
NSAID non response
Immunosuppression
Oral anticoagulation
Trauma
Suspected bacterial or tuberculous pericarditis
Higher level of care criteria
Hemodynamic instability
ICU level monitoring
Significant myocardial involvement
LV dysfunction or malignant arrhythmia risk
Transfer triggers
Need for pericardiocentesis or surgical drainage without local capability
Early cardiology and cardiothoracic consultation
Discharge and follow up
Outpatient eligibility
Hemodynamic stability
No syncope or hypotension
Low risk profile
No large effusion
No myocarditis phenotype
Symptom control
Pain improved on therapy in ED
Follow up plan
Cardiology or primary care follow up
Within 1 week if first episode
Repeat CRP
Trend to guide taper and activity progression
Repeat echocardiography when indicated
Any effusion
Persistent symptoms
Treatment
First line anti inflammatory therapy
Core strategy
NSAID or aspirin plus colchicine
Standard first line regimen in acute pericarditis
Gastroprotection
Proton pump inhibitor with NSAID or aspirin per ESC guidance
NSAID options
Ibuprofen PO
600 mg every 6 to 8 hours
Taper after symptom and CRP improvement
Naproxen PO
500 mg every 12 hours
Taper after symptom and CRP improvement
Indomethacin PO
50 mg every 8 hours
Avoid in older adults when possible due to CNS and GI toxicity
Aspirin PO
650 to 1000 mg every 6 to 8 hours
Preferred option after MI or when antiplatelet therapy required
Colchicine adjunct
Adults 70 kg or more
0.5 mg PO twice daily
Duration at least 3 months for first episode per ESC guidance
Adults less than 70 kg
0.5 mg PO once daily
Duration at least 3 months for first episode per ESC guidance
Dose adjustment and avoidance
Severe renal impairment
Reduce dose and extend dosing interval based on local formularies
Significant hepatic impairment
Avoid or reduce due to toxicity risk
Strong CYP3A4 or P glycoprotein inhibitors
Avoid combination due to myotoxicity and cytopenia risk
Activity restriction
Non athletes
Avoid strenuous exercise until symptom free and CRP normalized
Competitive athletes
Restriction for at least 3 months and until clinical and biomarker resolution per guideline consensus
Second line and refractory therapy
Corticosteroids
Indications
NSAID contraindication
Autoimmune flare with specialist input
Pregnancy with limited alternatives when active disease persists
Prednisone or equivalent
0.2 to 0.5 mg per kg per day
Slow taper to reduce recurrence risk
Avoidance
Routine first line use due to higher recurrence risk
IL 1 pathway inhibition for recurrent disease
Anakinra
Consider in colchicine resistant steroid dependent recurrent pericarditis
Specialist initiation and infection screening
Rilonacept
Consider in recurrent pericarditis with inflammatory phenotype
Specialist initiation and lipid monitoring
Tamponade and large effusion interventions
Pericardiocentesis
Indications per ESC 2025
Cardiac tamponade physiology
Symptomatic moderate to large effusion not responding to medical therapy
Diagnostic sampling when bacterial or malignant cause suspected
Drainage principles per ESC 2025
Limit initial rapid drainage to reduce decompression syndrome risk
Consider less than 500 mL at initial drainage when feasible
Catheter drainage
Leave drain until daily output low
Removal when daily drainage less than 30 mL per ESC 2025
Surgical drainage
Indications
Purulent effusion for complete drainage
Failed or not feasible percutaneous drainage
Etiology specific therapy
Purulent bacterial pericarditis
Broad spectrum IV antibiotics
Tailor to cultures and gram stain
Drainage
Early surgical drainage consideration
Tuberculous pericarditis
Anti tuberculosis regimen per local TB protocols
Specialist coordination recommended
Uremic pericarditis
Dialysis optimization
NSAID often avoided due to renal status
Post MI pericarditis
Aspirin preferred anti inflammatory
Avoid non aspirin NSAIDs due to infarct healing concerns
Special Populations
Pregnancy
Diagnostic priorities
Echocardiography first line imaging
No radiation
Alternate diagnosis vigilance
PE risk higher in pregnancy
Medication selection
NSAID timing constraints
Avoid systemic NSAIDs at 20 weeks or later due to oligohydramnios risk and fetal renal effects
Avoid in third trimester due to ductus arteriosus constriction risk
Aspirin
Low dose aspirin generally compatible when indicated
Colchicine
Considered safe in pregnancy and breastfeeding in ESC patient guidance
ESC 2025 slide set lists colchicine as IIb level C for pregnancy use
Corticosteroids
Low dose prednisone preferred when needed
Slow taper to minimize recurrence
Anakinra
ESC 2025 slide set includes consideration through pregnancy and lactation for refractory recurrent cases
Team based care
Obstetrics maternal fetal medicine involvement
Medication risk balancing and fetal monitoring plan
Geriatric
Atypical presentations
Less pleuritic or positional pain
Higher misdiagnosis risk for ACS
Lower fever response
Infection still possible
Medication risk mitigation
NSAID adverse effects
GI bleed risk increased
Renal injury risk increased
Colchicine toxicity
Dose reduction for renal impairment
Drug drug interactions with statins and macrolides
Disposition bias
Lower threshold for admission
Comorbidity burden and higher complication risk
Pediatrics
Presentation considerations
Viral triggers common
Fever and chest pain or abdominal pain patterns
Myocarditis overlap higher concern
Syncope exercise intolerance
Weight based therapy
Ibuprofen dosing
10 mg per kg PO every 6 to 8 hours
Maximum single dose per local pediatric formulary
Colchicine dosing
Age and weight based dosing per pediatric cardiology guidance
Avoid adult fixed dosing without specialist input
Disposition
Pediatric cardiology involvement
Any effusion
Troponin elevation
ECG abnormalities beyond typical pattern
Background
Epidemiology
Frequency
Common cause of non ischemic chest pain presentations
Accounts for a small proportion of cardiovascular admissions in ESC 2015 guidance
Recurrence risk
Recurrence in about 30 percent within 18 months after first episode reported in ESC 2015 guidance
Etiology distribution
Idiopathic or viral predominance in high income settings
Specific causes more likely with risk features
Pathophysiology
Inflammatory mechanisms
Pericardial inflammation
Pain from parietal pericardium irritation
Cytokine driven recurrence pathways
IL 1 mediated autoinflammation in recurrent phenotypes
Effusion formation
Increased permeability and fluid accumulation
Inflammation related effusions with elevated CRP
Non inflammatory effusions
Malignancy hypothyroidism uremia patterns
Tamponade physiology
Intrapericardial pressure rise
Impaired diastolic filling
Rate dependent risk
Small rapid effusions can tamponade
Large slow effusions may be tolerated until late
Therapeutic Considerations
Anti inflammatory goals
Pain relief
Symptom control early
Inflammation suppression
CRP guided taper to reduce recurrence
Colchicine mechanism
Microtubule inhibition and inflammasome modulation
Reduced recurrence risk in multiple trials summarized in contemporary reviews
Steroid concerns
Higher recurrence and dependency risk
Reserve for selected indications
Interventional balance
Drainage for tamponade or diagnostic need
Avoid excessive rapid drainage to reduce decompression syndrome risk per ESC 2025
Patient Discharge Instructions
copy discharge instructions
Home care and medications
NSAID or aspirin schedule as prescribed
Take with food
Colchicine as prescribed
Stop and seek care for severe diarrhea or muscle pain
Proton pump inhibitor if prescribed
Daily while on high dose NSAID or aspirin
Activity
No strenuous exercise until pain free and cleared by clinician
Athletes require longer restriction
Follow up
Follow up appointment arranged within 1 week
Repeat blood test plan for CRP if ordered
Repeat echocardiogram plan if effusion present
Timing per clinician
Return to ED now for red flags
Fainting or near fainting
Possible hemodynamic compromise
Worsening shortness of breath
Possible effusion progression or PE
Chest pain not improving or rapidly worsening
Alternate diagnosis concern
New fever or chills
Infection concern
Palpitations with dizziness
Arrhythmia concern
Swelling of legs or rapid weight gain
Heart failure concern
New confusion or severe weakness
Shock or serious illness concern
References
Clinical Guidelines and consensus
Guideline sources
2025 ESC Guidelines for the management of myocarditis and pericarditis
Colchicine recommended to prevent recurrence with at least 3 months in first episode per guideline narrative
Pericardiocentesis indicated for tamponade and symptomatic moderate to large effusions per guideline narrative
2015 ESC Guidelines for the diagnosis and management of pericardial diseases
Risk stratification and traditional diagnostic criteria framework
2025 clinical guidance on diagnosis and management of pericarditis
NSAID or aspirin plus colchicine framework and dosing overview
Safety references
FDA safety communication on NSAID use in pregnancy at 20 weeks or later
Oligohydramnios and fetal kidney risk
ESC patient guideline myocarditis and pericarditis
Colchicine pregnancy and breastfeeding reassurance
Source instructions
Evidence based sources and reviews
Contemporary reviews
Acute pericarditis update review articles
Diagnostic and management summaries
ACC clinical summaries on pericarditis and recurrent pericarditis
IL 1 inhibitor role in refractory recurrent cases
Evidence levels mapping
Recommendation grading conventions
ESC Class I IIa IIb III recommendations with level of evidence A B C
Used for myocarditis and pericarditis guideline statements
ACEP Level A B C reference framework
No dedicated ACEP clinical policy specific to isolated acute pericarditis in current public guidance
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.